|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
Heat Biologics, Inc. (HTBX) |
|
|
$0.93 0.00 (0.00%) as of 4:30 Thu 12/10
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
18,352,000 |
| Market
Cap: |
17.06(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.9295 - $0.9295 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile NightHawk Biosciences is a biopharmaceutical company focusing on the development and commercialization of therapies that arm the immune system against a range of diseases including cancer and infectious disease. Co.'s gp96 platform and RapidVax® platforms are designed to utilize the ability of gp96 to constitutively transport predefined antigens of interest to antigen presenting cells that in turn stimulate an antigen-specific immune response that includes B cells, CD4+ T-cells, and cytotoxic CD8+ T-cells. HS-110 (viagenpumatucel-L), an allogeneic therapy, is Co.'s main gp96 asset having completed Phase 2 enrollment of a non-small cell lung cancer clinical trial.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Wolf Jeffrey Alan |
Chief Executive Officer |
• • – |
2021-12-13 |
4 |
A |
$0.00 |
$0 |
D/D |
246,305 |
1,072,789 |
|
- |
|
| Prendergast John K A |
Director |
– • – |
2021-05-14 |
4 |
S |
$5.87 |
$205,293 |
D/D |
(35,000) |
203,272 |
|
- |
|
| Wolf Jeffrey Alan |
Chief Executive Officer |
• • – |
2021-01-04 |
4 |
A |
$0.00 |
$0 |
D/D |
288,100 |
766,484 |
|
- |
|
| Prendergast John K A |
Director |
– • – |
2021-01-04 |
4 |
A |
$0.00 |
$0 |
D/D |
138,272 |
238,272 |
|
- |
|
| Smith Edward B Iii |
Director |
– • – |
2020-11-12 |
4 |
S |
$1.03 |
$106,403 |
I/I |
(103,304) |
0 |
|
11% |
|
| Ostrander William L. |
VP Finance/Corp Secy |
• – – |
2020-08-13 |
4 |
D |
$1.83 |
$8,125 |
D/D |
(4,440) |
11,185 |
|
- |
|
| Ostrander William L. |
VP Finance/Corp Secy |
• – – |
2020-08-13 |
4 |
OE |
$0.52 |
$8,125 |
D/D |
15,625 |
15,625 |
|
- |
|
| Wolf Jeffrey Alan |
Chief Executive Officer |
• • – |
2020-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
1,980,000 |
3,768,693 |
|
- |
|
| Prendergast John K A |
Director |
– • – |
2020-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
400,000 |
700,000 |
|
- |
|
| Wolf Jeffrey Alan |
Chief Executive Officer |
• • – |
2019-12-31 |
4 |
A |
$0.00 |
$0 |
D/D |
900,000 |
1,788,693 |
|
- |
|
| Wolf Jeffrey Alan |
Chief Executive Officer |
• • • |
2019-12-30 |
4/A |
A |
$0.00 |
$0 |
D/D |
900,000 |
1,788,693 |
|
- |
|
| Wolf Jeffrey Alan |
Chief Executive Officer |
• • – |
2019-01-01 |
4/A |
A |
$0.00 |
$0 |
D/D |
800,000 |
888,693 |
|
- |
|
| Hutchins Jeff Tobin |
Chief Scientific Officer |
• – – |
2019-01-01 |
4 |
A |
$0.00 |
$0 |
D/D |
143,140 |
143,140 |
|
- |
|
| Prendergast John K A |
Director |
– • – |
2019-01-01 |
4 |
A |
$0.00 |
$0 |
D/D |
300,000 |
300,000 |
|
- |
|
| Wolf Jeffrey Alan |
Chief Executive Officer |
• • – |
2019-01-01 |
4 |
A |
$0.00 |
$0 |
D/D |
800,000 |
848,317 |
|
- |
|
| Rosar Ann A |
VP of Finance |
• – – |
2019-01-01 |
4 |
A |
$0.00 |
$0 |
D/D |
89,430 |
93,379 |
|
- |
|
| Wolf Jeffrey Alan |
Chief Executive Officer |
• • – |
2018-01-08 |
4 |
A |
$0.00 |
$0 |
D/D |
665,720 |
886,950 |
|
- |
|
| Rosar Ann A |
VP of Finance |
• – – |
2018-01-08 |
4 |
A |
$0.00 |
$0 |
D/D |
45,000 |
108,236 |
|
- |
|
| Smith Edward B Iii |
Director |
– • – |
2017-04-28 |
4 |
A |
$0.00 |
$0 |
I/I |
335,743 |
1,033,046 |
|
- |
|
| Smith Edward B Iii |
Director |
– • – |
2017-04-28 |
4 |
A |
$0.00 |
$0 |
D/D |
10,010 |
10,010 |
|
- |
|
| Wolf Jeffrey Alan |
Chief Executive Officer |
• • – |
2017-04-28 |
4 |
A |
$0.00 |
$0 |
I/I |
255,403 |
716,195 |
|
- |
|
| Wolf Jeffrey Alan |
Chief Executive Officer |
• • – |
2017-04-28 |
4 |
A |
$0.00 |
$0 |
D/D |
16,349 |
221,230 |
|
- |
|
| Monahan John J |
Director |
– • – |
2017-04-28 |
4 |
A |
$0.00 |
$0 |
D/D |
3,958 |
5,169 |
|
- |
|
| Rosar Ann A |
VP of Finance |
• – – |
2017-02-07 |
4 |
D |
$0.88 |
$5,936 |
D/D |
(6,764) |
63,236 |
|
- |
|
| Wolf Jeffrey Alan |
Chief Executive Officer |
• • – |
2017-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
125,000 |
204,881 |
|
- |
|
44 Records found
|
|
Page 1 of 2 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
